The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.
Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology volume 31 (2020) 1476–1490, (S0923753420421076), (10.1016/j.annonc.2020.08.2099)]
Berruti A.
2022-01-01
Abstract
The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
